ocket Number: D-2939CIP



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

in re Application of: Williams et al.

U.S. Serial No: 08/704,159

Filed: August 28, 1996

For: MULTIVALENT VACCINE FOR

CLOSTRIDIUM BOTULINUM

NEUROTOXIN

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal service as first class mail in an envelope addressed to:

Box Responses-no fee Commissioner for Patents Washington, D. C. 20231 on March 23, 2001.

Signed Dave House Date: March 23, 2001

BOX RESPONSES - NO FEE Commissioner for Patents Washington, D.C. 20231 Group Art Unit: 1648

Examiner: Li, B.

RECEIVED

MAR 3 0 2001

TECH CENTER 1600/2900

RESPONSE TO RESTRICTION REQUIREMENT

Dear Sir:

Responsive to the Restriction Requirement mailed on February 26, 2001, applicant hereby elects Group I invention, as set forth in claims 42-45, 54-65 and 79-109 with traverse.

Furthermore, applicant respectfully disagrees with the Examiner's subclassification of Groups I or II into i-xxvi. It is well known that "The botulinum toxins comprise a family of pharmacologically similar toxins [e.g. serotypes A through G] that block acetylcholine release from peripheral nerves and cause a flaccid paralysis. All of the serotypes of toxin can poison humans and other animals..." Page 81, left hand side of Schantz, E.J., et al., *Properties and use of Botulinum toxin and Other Microbial Neurotoxins in Medicine*, Microbiol Rev. 56;80-99:1992. (Attached)

Respectfully submitted,

Quan L. Nguyen

Registration Number: 46,957

March 23, 2001 Stout, Uxa, Buyan & Mullins LLP 4 Venture, Suite 300, Irvine, CA 92618 phone: 949-450-1750 fax: 949-450-1764